J Korean Med Assoc.  2007 Sep;50(9):842-847. 10.5124/jkma.2007.50.9.842.

Current Concepts and Therapeutic Management of Dry Eye

• Chun YS

• KMID: 2184926
• DOI: http://doi.org/10.5124/jkma.2007.50.9.842

Abstract

The majority of dry eye symptoms are due to a chronic inflammation of the lacrimal functional unit resulting in a loss of tear film integrity and normal function. The tear secretion is controlled by the lacrimal functional unit consisting of the ocular surface (cornea, conjunctiva, and meibomian glands), the main lacrimal gland, and the interconnecting innervation. A lack of systemic androgen support to the lacrimal gland has been shown to be a facilitating factor in the initiation of ocular inflammation. If any portion of this functional unit is compromised, lacrimal gland support to the ocular surface is impeded. In this review, the classification and treatment of dry eye syndrome will be presented according to the A Delphi approach.

Keyword

Cyclosporine; Dysfunctional tear syndrome; Lacrimal functional unit

MeSH Terms

Classification
Conjunctiva
Cyclosporine
Dry Eye Syndromes
Inflammation
Lacrimal Apparatus
Tears
Cyclosporine

Reference

1. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004. 78:409–416.

2. Lemp MA, Baudouin C, Baum J, Dogru M, Foulks GN, Kinoshita S, Laibson P, McCulley J, Murube J, Pfugfelder SC, Rolando M, Toda I. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007. 5:75–92.

3. Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, Dua HS, Hom M, Karpecki PM, Laibson PR, Lemp MA, Meisler DM, Del Castillo JM, O'Brien TP, Pflugfelder SC, Rolando M, Schein OD, Seitz B, Tseng SC, van Setten G, Wilson SE, Yiu SC. Dysfunctional tear syndrome study group. Dysfunctional tear syndrome. A Delphi approach to treatment recommendations. Cornea. 2006. 25:900–907.

4. Aragona P, Bucolo C, Spinella R, Giuffrida S, Ferreri G. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren's syndrome patients. Invest Ophthalmol Vis Sci. 2005. 46:4474–4479.

5. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007. 114:76–79.